Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

Conditions:   Herpes Zoster;   Shingles Interventions:   Biological: CRV-101 Vaccine Antigen High Dose;   Biological: CRV-101 Vaccine Antigen Low Dose;   Biological: Shingrix Sponsors:   Curevo Inc;   Mogam Biotechnology Research Institute;   Green Cross Corporation Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials